The transition from relapsing-remitting MS to irreversible disability: clinical evaluation

The development of a progressive course is by far the most deleterious event in the case of a multiple sclerosis (MS) patient. It occurs in about 90% of relapsing remitting patients by 20-25 years from onset. The clinical transition to secondary progressive MS is phenotypically distinctive and both...

Full description

Saved in:
Bibliographic Details
Published in:Neurological sciences 2003-12, Vol.24 Suppl 5, p.S268-s270
Main Authors: Trojano, M, Paolicelli, D, Bellacosa, A, Cataldo, S
Format: Article
Language:English
Subjects:
Adult
Age Factors
Clinical Trials as Topic
Disability Evaluation
Disease Progression
Female
Humans
Male
Multiple Sclerosis, Chronic Progressive - physiopathology
Multiple Sclerosis, Relapsing-Remitting - physiopathology
Neurology
Neurosciences
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The development of a progressive course is by far the most deleterious event in the case of a multiple sclerosis (MS) patient. It occurs in about 90% of relapsing remitting patients by 20-25 years from onset. The clinical transition to secondary progressive MS is phenotypically distinctive and both patients and physicians acknowledge that a fundamental shift in the degree of responsiveness to anti-inflammatory therapies has occurred. This review discusses the clinical studies that provided important findings relating to our understanding on different mechanisms that may contribute to irreversible disability in MS.
ISSN:1590-1874
1590-3478
DOI:10.1007/s10072-003-0171-6